Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray(University of Maryland, Baltimore), J. Wouter Jukema(Leiden University Medical Center), Andrzej Budaj, Deepak L. Bhatt(Mount Sinai Hospital), Rafael Díaz(Estudios Clínicos Latinoamérica), Virginie Loizeau(Sanofi (France)), Marie T. Baccara‐Dinet(Sanofi (France)), Philip E. Aylward(Flinders Medical Centre), Peter Sinnaeve(Brigham and Women's Hospital), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Robert Pordy(Inserm), Vera Bittner(University of Alabama at Birmingham), Robert A. Harrington(Clinical Research Institute), Andreas M. Zeiher(Goethe University Frankfurt), Harvey D. White(University of Auckland), Gregory G. Schwartz(University of Colorado Denver), José Tuñón(Universidad de Jaén), Renato D. Lópes(Duke University), Michael Szarek(St. Michael's Hospital), Heinz Drexel(ESCP Business School), Arsen Ristić(University of Belgrade), Pierluigi Tricoci(Duke University), Corinne Hanotin(Sanofi (France)), Mirza Dilić(Duke University), Shaun G Goodman(St. Michael's Hospital), Jay M. Edelberg(Inserm), Angèle Moryusef(Inserm), Robert A Harrington(Center for Clinical Research (United States)), William J. Sasiela(Inserm), Guillaume Lecorps(Sanofi (United States)), Matthew T. Roe(Inserm), Jean‐François Tamby(Medical University of South Carolina), Shaun G. Goodman, Jan Murin(University Hospital Bratislava), Philippe Gabríel Steg(Mount Sinai Hospital), Helen M Colhoun(University of Edinburgh)
The Lancet Diabetes & Endocrinology
July 1, 2019
Cited by 330


Related Papers